A Historical Perspective of Anthracycline Cardiotoxicity

摘要: Anthracyclines remain important agents in the treatment of solid and hematological malignancy. Early experience with these drugs reported cardiac failure as an adverse event. Later, clinical recognition cell injury at time administration was appreciated. This article explores evolution our understanding about anthracycline-associated cardiotoxicity, including various strategies for pretreatment assessment patients whom anthracyclines are contemplated, frustrations associated lack specific tests that could identify risk developing problems their next 1 or 2 cycles, concept balancing oncologic benefit cancer patients, newer reducing potentially devastating complications malignant disease anthracyclines.